Sanbexin (edaravone dexborneol) / Simcere - LARVOL DELTA

Cost-effectiveness of edaravone dexborneol sublingual tablet versus concentrated solution for injection for the treatment of acute ischemic stroke in China. (PubMed, Front Pharmacol) - "EDSL represents a more cost-effective therapy for AIS patients compared to EDCSI, offering comparable efficacy at a lower drug cost. A full 14-day treatment course may help maximize patient benefits."

HEOR • Journal • Cardiovascular • Ischemic stroke

Efficacy and safety of Edaravone Dexborneol in acute large vessel occlusion patients with successful recanalization after endovascular treatment. (PubMed, J Stroke Cerebrovasc Dis) - "Among AIS-LVO patients with successful recanalization after EVT, ED may be associated with an improved functional outcome without an increased risk of sICH and mortality."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

A Novel Mutation in Exon 10 of the NOTCH3 Gene in Human Cerebral Microvascular Endothelial Cells Induces CADASIL-Like Pathology and the Therapeutic Effect of Edaravone Dexborneol on Hereditary and Non-hereditary Cerebral Small Vessel Disease. (PubMed, Neurochem Res) - "The progression of CADASIL is intensified by a cascade of interactions between compromised hCMEC and surrounding neurons and glial cells. EDB may offer a promising therapeutic approach for cerebral small vessel disease including CADASIL and non-hereditary one."

Journal • Cardiovascular • CNS Disorders • Inflammation • Ischemic stroke • Solid Tumor • ASS1 • NOTCH3

Edaravone Dexborneol Attenuates Cerebral Ischemia-Reperfusion Injury via cGAS-STING Inhibition, STX17-Mediated Autophagic Flux Restoration, and NLRP3 Inflammasome Suppression. (PubMed, Eur J Pharmacol) - "In conclusion, this study identifies a novel mechanism whereby EDB alleviates CI/RI through dual regulation of autophagy and inflammation via inhibition of cGAS-STING signaling. These findings not only provide new mechanistic insights but also support the clinical potential of EDB as an adjunctive therapy for AIS reperfusion injury."

Journal • Cardiovascular • Inflammation • Ischemic stroke • Reperfusion Injury • CGAS • NLRP3 • STING

Edaravone dexborneol attenuates neuroinflammation in acute cerebral ischemia-reperfusion injury through the CXCL13/CXCR5/NF-κB pathway. (PubMed, Immunopharmacol Immunotoxicol) - "Our results validate the protective efficacy of Edaravone dexborneol in OGD/R-induced microglia and MCAO rats. This effect may be attributed to its ability to mitigate neuroinflammation by modulating microglial M1/M2 polarization in vitro and inhibiting the CXCL13/CXCR5 axis and its associated NF-κB signaling pathway in vivo."

Journal • Cardiovascular • Inflammation • Ischemic stroke • Reperfusion Injury • CXCL13 • CXCR5 • IL1B • TNFA

Edaravone Dexborneol in acute ischemic stroke patients treated with combined intravenous thrombolysis and mechanical thrombectomy for large vessel occlusion. (PubMed, Front Neurol) - "Patients treated with Edaravone Dexborneol were associated with better functional outcomes three months after stroke onset compared to those who did not receive the treatment. These findings may be related to the drug's anti-inflammatory properties; however, randomized controlled trials are needed to confirm efficacy in patients undergoing MT combined with IVT."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • IL10 • IL1B • IL6 • TGFB1 • TNFA

Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and meta-analysis. (PubMed, Front Neurol) - "The promising efficacy of this compound underscores the necessity for further comprehensive global studies aimed at optimizing its application and enhancing its relevance across diverse populations. https://www.crd.york.ac.uk/prospero/, identifier CRD42024626320."

Journal • Retrospective data • Review • Cardiovascular • CNS Disorders • Depression • Hematological Disorders • Inflammation • Ischemic stroke • Psychiatry

Clinical efficacy of edaravone dexborneol in the treatment of acute ischemic stroke: meta-analysis. (PubMed, Front Neurol) - "The results showed that the funnel plot of the NIHSS scores and hs-CRP were basically symmetrical. While ED demonstrates short-term efficacy in improving neurological outcomes, its clinical applicability remains uncertain due to unresolved questions about drug diffusion and delivery in human brain tissue, which may fundamentally limit its long-term benefits."

Journal • Retrospective data • Review • Cardiovascular • Ischemic stroke

Clinical and Safety Outcomes of Edaravone Dexborneol in Acute Ischemic Stroke: A Multicenter, Prospective, Cohort Study. (PubMed, Neurology) - P=N/A | "In this observational cohort study involving Chinese patients with AIS, edaravone dexborneol was associated with significantly better functional outcome at 90 days. Verification of our findings is warranted in other populations."

Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke

S100A11 mediates the protective effects of edaravone dexborneol on docetaxel-induced cognitive impairment in rats by inhibiting the MAPK signaling pathway. (PubMed, Toxicol Appl Pharmacol) - "Further rescue experiments showed that S100A11 knockdown reversed the defensive role of ED in DTX-induced neuronal damage. In conclusion, ED ameliorates cognitive dysfunction caused by DTX by upregulating the S100A11 expression and subsequently inactivating the MAPK signaling pathway."

Journal • Preclinical • Alzheimer's Disease • Cognitive Disorders • S100A11

PRECISE AM: A Prospective, Multicentre, Randomized Controlled Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy (clinicaltrials.gov) - P4 | N=144 | Not yet recruiting | Sponsor: Nanfang Hospital, Southern Medical University

New P4 trial • Cardiovascular • Ischemic stroke • Oncology

Edaravone dexborneol compared to edaravone in the treatment of acute cerebral infarction: A meta-analysis. (PubMed, Front Pharmacol) - "Fourteen days after treatment, the edaravone dexborneol group showed significantly better scores than the edaravone group in the NIHSS (MD = -2.13, 95% CI [-2.90, -1.35], p < 0.00001), Barthel Index (MD = 12.13, 95% CI [7.68, 16.58], p < 0.00001), and modified Rankin Scale (MD = -1.16, 95% CI [-1.75, -0.56], p = 0.0001). Edaravone dexborneol demonstrates superior clinical efficacy and safety compared to edaravone in the treatment of acute cerebral infarction, suggesting it may be a more effective therapeutic option."

Journal • Retrospective data • Review • CNS Disorders

Efficacy and Safety of Butylphthalide Combined with Edaravone Dexborneol in Acute Ischemic Stroke Patients Undergoing Thrombectomy (ChiCTR) - P4 | N=702 | Recruiting | Sponsor: Drum Tower Hospital; Drum Tower Hospital

New P4 trial • Cardiovascular • Ischemic stroke

EFFECTIVENESS OF EDARAVONE DEXBORNEOL IN REAL-WORLD PATIENTS WITH MODERATE AND SEVERE ACUTE ISCHEMIC STROKE (ESOC 2025) - P=N/A | "Edaravone dexborneol is associated with higher odds of excellent functional outcomes among patients with moderate to severe AIS compared to those not receiving the treatment."

Clinical • Real-world • Real-world evidence • Cardiovascular • Ischemic stroke

TREATMENT OF ACUTE ISCHEMIC STROKE WITH EDARAVONE DEXBORNEOL IN SMALL VESSEL DISEASE (TASTE-SVD) (ESOC 2025) - P3 | "TASTE-SVD seeks to establish edaravone dexborneol sublingual tablets as a treatment option for acute ischemic SVD, targeting specific pathological mechanisms in SVD to slow disease progression and improve cognitive and functional outcomes"

Cardiovascular • Ischemic stroke

EDARAVONE DEXBORNEOL FOR ACUTE ISCHEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS (ESOC 2025) - "Edaravone Dexborneol significantly improves functional and neurological recovery in AIS with a favorable safety profile. Figure 1: Forest plot showing NIHSS Figure 2: Forest plot showing mRS available data"

Retrospective data • Review • Cardiovascular • Ischemic stroke

EFFICACY AND SAFETY OF EDARAVONE DEXBORNEOL IN ACUTE ISCHEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (ESOC 2025) - "The neuroprotective clinical benefits of Edaravone Dexborneol in AIS are encouraging, improving functional outcomes and reducing hemorrhagic transformation risk. Further large-scale RCTs are needed to confirm these findings and confirm its efficacy and safety."

Retrospective data • Review • Cardiovascular • Ischemic stroke

EDARAVONE DEXBORNEOL IN LARGE ISCHEMIC STROKE: REAL-WORLD EXPERIENCE FROM MULTICENTER IN CHINA (ESOC 2025) - "In AIS patients with large infarction, edaravone dexborneol improved the likelihood of achieving favorable functional outcomes at 90 days."

Clinical • Real-world • Real-world evidence • Cardiovascular • Ischemic stroke

Edaravone dexborneol provides neuroprotective benefits by suppressing ferroptosis in experimental intracerebral hemorrhage. (PubMed, Sci Rep) - "Besides, the P53 inhibitor PFT-α was observed to significantly reduce the levels of 4-HNE and lipid peroxides, while concurrently increasing the expression of GPX4. This investigation has shed light on the crucial neuroprotective role of EDB by regulating ferroptosis in ICH disease, which provided a theoretical basis for the clinical application of EDB in the treatment of ICH."

Journal • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Vascular Neurology • GPX4

Edaravone dexborneol protected neurological function by targeting NRF2/ARE and NF-κB/AIM2 pathways in cerebral ischemia/reperfusion injury. (PubMed, Front Pharmacol) - "Moreover, Eda-Dex clearly reduced pathological damage, rescued neurons, and reduced the activation of microglia and astrocytes. The results of this study confirm that Eda-Dex exerts neuroprotective effects by synergistically inhibiting oxidative stress and inflammation via the NRF2/ARE and NF-κB/AIM2 pathways in CIRI rats."

Journal • Cardiovascular • Inflammation • Psychiatry • Reperfusion Injury • NQO1 • SLC7A11

Edaravone dexborneol for the treatment of acute ischemic stroke: A systematic review and meta-analysis. (PubMed, Neuroradiol J) - "No heterogeneity in treatment effect was seen in the analysis, and any potential discrepancies were addressed by sensitivity analysis.ConclusionEdaravone dexborneol can be a favorable treatment option for patients with stroke. However, more randomized controlled trials are required to confirm our findings."

Journal • Retrospective data • Review • Cardiovascular • Ischemic stroke

Effect of edaravone dexborneol combined with interventional thrombectomy on nerve function, cerebral hemodynamics, and serum levels of serum amyloid A, lipoprotein-associated phospholipase A2, and soluble CD40 ligand in elderly patients with ischemic stroke. (PubMed, J Physiol Pharmacol) - "BDNF, NGF, and SOD in the observation group were higher than those in the control group, and NSE, MDA, and NEF were lower (P<0.05). ED combined with interventional thrombectomy in the treatment of IS in the elderly can improve nerve function, alleviate oxidative stress reaction, reduce levels of SAA, LP-PLA2, and sCD40L, and alleviate inflammatory response."

Clinical • Journal • Cardiovascular • Inflammation • Ischemic stroke • BDNF • CD40LG

Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial. (PubMed, Nat Commun) - P2 | "The proportion of patients with 90-day mRS (0-2) was 58.7% (54/92) in ED group and 52.1% (49/94) in control group (unadjusted odds ratio 1.37, [95% CI 0.76-2.44], P = 0.29). This work suggests that intravenous ED is safe, but do not statistically improve 90-day functional outcomes in patients with anterior circulation stroke with successful endovascular reperfusion."

Clinical • Journal • P2 data • Cardiovascular • Ischemic stroke

Edaravone dexborneol exerts anti-epileptic effects on rodent temporal lobe epilepsy by promoting NMDAR deactivation and inhibiting oxidative stress. (PubMed, Phytomedicine) - "Edaravone Dexborneol exhibits antiepileptic effects and may fill the gap in disease-modifying treatments for TLE."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Epilepsy • Metabolic Disorders

Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and meta-analysis of randomized controlled trials. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "ED demonstrates significant neuroprotective benefits in AIS by improving functional outcomes and reducing the risk of hemorrhagic transformation. However, further studies with larger sample sizes must confirm these findings and optimize treatment protocols."

Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Ischemic stroke